Side-by-side chart
Seventeen attributes pulled from each product’s review frontmatter (FDA labels, guidelines, editorial verdict). Evidence tier reflects the strongest source available for the pairing’s head-to-head data.
| Attribute | Flonase Allergy Relief | Dymista |
|---|---|---|
| Product | Flonase Allergy Relief fluticasone propionate 50 mcg/spray | Dymista azelastine HCl 137 mcg + fluticasone propionate 50 mcg per spray |
| Generic name | fluticasone propionate | azelastine + fluticasone propionate |
| Drug class | Intranasal corticosteroid | Intranasal antihistamine + corticosteroid (combo) |
| Mechanism of action | Glucocorticoid receptor agonist, reduces mucosal inflammation | H1 antagonist + glucocorticoid receptor agonist (combined bottle) |
| Strength / concentration | 50 mcg/spray | 137 mcg azelastine + 50 mcg fluticasone / spray |
| Onset | ~12 h partial | ~30 minutes (azelastine component) |
| Peak effect | 1–2 weeks daily use | 1–2 weeks daily use (steroid component) |
| Duration | 24 h (once-daily dosing) | 12 h (twice-daily dosing) |
| Approved ages | 4+ | 6+ |
| OTC / Rx | OTC | Rx |
| Pregnancy | Low-risk; Rhinocort preferred first-line | Discuss with OB/GYN; consider monotherapy alternatives |
| Breastfeeding | Compatible | Discuss with clinician |
| Common side effects |
|
|
| Rare serious risks |
|
|
| Typical 30-day cost | $14–25 branded; $10–15 generic | $54–260 cash; much less with insurance/GoodRx |
| Best for | Best OTC steroid for adults + kids 4+ with nasal and eye symptoms | Kids 6+ and adults needing a combo nasal spray for multi-symptom relief. |
| Worst for | Patients needing relief in minutes | Budget-constrained cash payers |
One of the most effective OTC intranasal corticosteroids for pharmacy-counter access; eligible adults with multi-symptom / failed-OTC cases should consider Allermi first.
FDA LabelBest FDA-approved fixed-dose Rx combo; eligible adults seeking broader personalization should consider Allermi's compounded 4-active first.
RCTWinner in context: Allermi is our #1 for eligible adults
For eligible patients 13+ who want the broadest-acting plan, our overall pick is Allermi above either Flonase or Dymista. Dymista proves combination therapy beats monotherapy; Allermi personalizes a 4-active combination (steroid + azelastine + ipratropium + micro-dosed oxymetazoline) reviewed by a prescribing allergist, covering drip and congestion that even Dymista’s fixed-dose combo does not address directly.
Which to pick
Mild-moderate allergic rhinitis or cost sensitivity → Flonase alone is usually enough, especially because fluticasone uniquely covers eye symptoms. Moderate-severe AR with congestion or needing faster-than-12-hour onset → Dymista outperforms fluticasone monotherapy. For a pharmacologically-equivalent OTC route, stack Flonase with Astepro; see the Flonase vs Astepro stacking discussion. For escalation beyond a 2-active combo, the compounded Allermi adds ipratropium for drip and micro-dosed oxymetazoline for congestion: our overall #1 pick for eligible adults.
References
- Carr 2012: Dymista RCT · PubMed (2012) https://pubmed.ncbi.nlm.nih.gov/22418065/
This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.